Xeljanz denied by insurance? Appeal and win.
A denial for Xeljanz is rarely the end of the road. It is usually the start of a process, and most denials turn on documentation rather than medical disagreement. Because Xeljanz is a high-cost oral JAK inhibitor that the FDA narrowed after the ORAL Surveillance safety study, plans almost always require a documented trial and failure of a TNF inhibitor before they will approve it, and the appeal that wins is the one that proves that history on paper.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Xeljanz (tofacitinib) is FDA approved for adults with moderately to severely active rheumatoid arthritis, adults with active psoriatic arthritis, adults with moderately to severely active ulcerative colitis, and adults with active ankylosing spondylitis. The immediate-release tablet and oral solution are also approved for children 2 years and older with active polyarticular juvenile idiopathic arthritis and with active psoriatic arthritis. For ulcerative colitis the FDA label limits use to patients who have had an inadequate response or intolerance to one or more TNF blocker medicines, and after the ORAL Surveillance safety study the label positions Xeljanz across its indications for use in patients who did not respond to or could not tolerate one or more TNF blockers.
Why Xeljanz gets denied
- Step therapy not satisfied: the plan requires a documented trial and failure of, or intolerance to, at least one TNF inhibitor (and often methotrexate) before a JAK inhibitor, and that history is missing from the request.
- Non-formulary or non-preferred status: the plan prefers a different agent such as a TNF inhibitor or a preferred JAK inhibitor, and routes Xeljanz to a higher tier or excludes it.
- Prior authorization criteria not documented: the submission lacks the diagnosis with ICD-10 code, disease activity measures, or specialist prescriber that the plan's policy demands.
- Post-ORAL Surveillance safety screening: the plan cites the boxed warnings and asks for documentation that a TNF inhibitor was tried first or is contraindicated, plus cardiovascular and malignancy risk review.
What a winning appeal includes
- A confirmed diagnosis with the matching ICD-10 code (for example M06.9 rheumatoid arthritis, L40.50 psoriatic arthritis, K51.90 ulcerative colitis, or M45 ankylosing spondylitis) and objective disease activity measures.
- A clear medication history listing each prior therapy by name, dose, dates, and the reason it failed or was stopped, especially the required TNF inhibitor and methotrexate trials.
- A letter of medical necessity that maps the patient's history point by point to the plan's own written coverage criteria and cites the FDA label.
- Baseline and monitoring documentation such as TB screening, hepatitis B and C status, CBC, and lipid panel, plus a note on cardiovascular and malignancy risk to address the boxed warnings.
How we approach the appeal
Start by pulling the plan's actual coverage policy for tofacitinib, because the path depends on why it was denied. If the issue is tier or formulary placement, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed; if it is a clinical denial, file a prior authorization appeal or medical necessity appeal that answers each criterion in the policy by name. Quote the plan's own language back to it, for example its requirement of an inadequate response or intolerance to a TNF blocker, and attach the records that satisfy that exact requirement so the reviewer can check each box.
Xeljanz appeal letter template
Copy this Xeljanz appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Janus kinase (JAK) inhibitor denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Xeljanz denial I am appealing the denial of Xeljanz (tofacitinib). I request that the denial be overturned and Xeljanz approved. 1. The denial. [Insurer] denied Xeljanz stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Xeljanz is medically necessary for my condition. Start by pulling the plan's actual coverage policy for tofacitinib, because the path depends on why it was denied. If the issue is tier or formulary placement, file a formulary or tier exception arguing that preferred alternatives are inappropriate or have failed; if it is a clinical denial, file a prior authorization appeal or medical necessity appeal that answers each criterion in the policy by name. Quote the plan's own language back to it, for example its requirement of an inadequate response or intolerance to a TNF blocker, and attach the records that satisfy that exact requirement so the reviewer can check each box. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Xeljanz within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Xeljanz denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why does my plan want me to try a TNF inhibitor before Xeljanz?
After the ORAL Surveillance safety study, the FDA positioned Xeljanz for patients who have had an inadequate response or intolerance to one or more TNF blockers, and most plans mirror that in their prior authorization rules. If you have already tried a TNF inhibitor like adalimumab or etanercept and it failed or you could not tolerate it, document those names, doses, dates, and outcomes. If a TNF inhibitor is medically contraindicated for you, have your prescriber state that clearly, because it can satisfy the requirement without an actual trial.
My plan covers the brand but put it on a high tier. Can I lower my cost?
Yes, you can request a tier or cost-share exception. This is separate from a medical necessity appeal and asks the plan to treat Xeljanz at a lower cost tier because the preferred alternatives are not suitable for you or have already failed. Your prescriber's supporting statement explaining why the preferred drugs are inappropriate is the key document, along with your prior therapy history.
Does a generic version change my appeal?
Tofacitinib is the generic name for Xeljanz, and generic tofacitinib has become available. If your plan prefers the generic, the same clinical criteria generally apply, so your prior therapy history and diagnosis documentation carry the appeal either way. If your prescriber wants the brand specifically, that request needs its own justification, but for most appeals confirming the diagnosis and documented TNF inhibitor trial is what matters most.
Xeljanz denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.